
Back to articles | News | Stocks
Razak Pharmaceutical (DRZK) Has Risen About 176% on an Adjusted Basis Since Its June 15 Reopening, Closing Each Session Bid-Locked; Behind the Run, a Jump in Quarterly Profit and a P/E Below the Sector Average
Sahmino Newsroom | 20 August 2026 | 7 min read
Razak Pharmaceutical (DRZK), halted for roughly four months, has climbed an adjusted 176% from its June 15, 2026 reopening to August 19, closing that last session at 3,980 rials on a buy queue, with volume about five times the one-month average. Behind the run sits the interim statement for the three months to June 21, 2026, in which net profit…
Related video
References
- CodalInterim financial statement for the three months to 31 Khordad 1405 (June 21, 2026), unaudited, tracing number 1569189, published 29 Tir 1405 (July 20, 2026); net profit up more than 15-fold and revenue up 92% year over year.Cited Aug 20, 2026
- TSETMCDRZK closing price on Wednesday, August 19, 2026 was 3,980 rials (up 2.84% from the prior close), EPS about 453 rials, and P/E about 8.8 versus a pharmaceutical sector average near 13.Cited Aug 20, 2026
Related articles
- Bitcoin Tops $72,000 to Its Highest Since Early June as the US Treasury Doubles Long-Term Bond Buybacks (Thursday, 20 August 2026)
- Sahmino's Screen Finds 4 High-Momentum Tehran Stock Exchange Sectors for the Week Ahead; Data Through Friday, August 21, 2026
- Bahman Motor Opens a Five-Model Auction on Saturday, August 22; Mazda3 Below Market Price as Its Stock Is Up 90 Percent Over the Past Year
- Saipa Opens Non-Lottery Registration for Quick, Aria and Pars Nova from Sunday, August 23; Its Stock Hits a One-Year High on a Seventh Straight Up Session




